Abstract
Aims
The impact of introducing new classes of glucose-lowering medication (GLM) on diabetes management remains unclear, especially outside North America and Western Europe. Therefore, we aimed to analyse trends in glycaemic control and the usage of new and old GLMs in people with type 2 diabetes from 2006 to 2015.
Methods
Summary data from clinical services from nine countries outside North America and Western Europe were collected and pooled for statistical analysis. Each site summarized individual-level data from out-patient medical records for 2006 and 2015. Data included: demographics; HbA1c and fasting plasma glucose levels; and the proportions of patients taking GLM as monotherapy, combination therapy and/or insulin.
Results
Between 2006 and 2015, glycaemic control remained stable, although body mass index and duration of diabetes increased in most sites. The proportion of people on GLM increased, and the therapeutic regimens became more complex. There were increases in the use of insulin and triple therapy in most sites, while monotherapy, particularly in relation to sulphonylureas, decreased. Despite the introduction of new GLMs, such as DPP-4 inhibitors, insulin use increased over time.
Conclusions
There was no clear evidence that the use of new classes of GLMs was associated with improvements in glycaemic control or reduced the reliance on insulin. These findings were consistent across a range of economic and geographic settings.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
International Diabetes Federation (2017) IDF Diabetes Atlas, 8th edn. International Diabetes Federation, Brussels
Collaboration NCDRF (2016) Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4.4 million participants. Lancet 387(10027):1513–1530. https://doi.org/10.1016/S0140-6736(16)00618-8
International Diabetes Federation (2015) IDF Diabetes Atlas, 7 edn. International Diabetes Federation, Brussels
Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA (2008) 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 359(15):1577–1589. https://doi.org/10.1056/NEJMoa0806470
Action to Control Cardiovascular Risk in Diabetes Study G, Gerstein HC, Miller ME et al (2008) Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358 (24):2545–2559. https://doi.org/10.1056/NEJMoa0802743
Vasilakou D, Karagiannis T, Athanasiadou E et al (2013) Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med 159(4):262–274. https://doi.org/10.7326/0003-4819-159-4-201308200-00007
Inzucchi SE, Bergenstal RM, Buse JB et al (2015) Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 38(1):140–149. https://doi.org/10.2337/dc14-2441
Looker HC, Krakoff J, Andre V et al (2010) Secular trends in treatment and control of type 2 diabetes in an American Indian population: a 30-year longitudinal study. Diabetes Care 33(11):2383–2389. https://doi.org/10.2337/dc10-0678
Raebel MA, Xu S, Goodrich GK et al (2013) Initial antihyperglycemic drug therapy among 241,327 adults with newly identified diabetes from 2005 through 2010: a surveillance, prevention, and management of diabetes mellitus (SUPREME-DM) study. Ann Pharmacother 47(10):1280–1291. https://doi.org/10.1177/1060028013503624
Liatis S, Dafoulas GE, Kani C et al (2016) The prevalence and treatment patterns of diabetes in the Greek population based on real-world data from the nation-wide prescription database. Diabetes Res Clin Pract 118:162–167. https://doi.org/10.1016/j.diabres.2016.06.018
Levin P, Wei W, Miao R et al (2015) Therapeutically interchangeable? A study of real-world outcomes associated with switching basal insulin analogues among US patients with type 2 diabetes mellitus using electronic medical records data. Diabetes Obes Metab 17(3):245–253. https://doi.org/10.1111/dom.12407
Lian J, Liang Y (2014) Diabetes management in the real world and the impact of adherence to guideline recommendations. Curr Med Res Opin 30(11):2233–2240. https://doi.org/10.1185/03007995.2014.952716
Filion KB, Joseph L, Boivin JF, Suissa S, Brophy JM (2009) Trends in the prescription of anti-diabetic medications in the United Kingdom: a population-based analysis. Pharmacoepidemiol Drug Saf 18(10):973–976. https://doi.org/10.1002/pds.1802
Torre C, Guerreiro J, de Oliveira Martins S, Raposo JF, Martins AP, Leufkens H (2015) Patterns of glucose lowering drugs utilization in Portugal and in the Netherlands. Trends over time. Prim Care Diabetes 9(6):482–489. https://doi.org/10.1016/j.pcd.2015.03.009
Hammer GP, du Prel JB, Blettner M (2009) Avoiding bias in observational studies: part 8 in a series of articles on evaluation of scientific publications. Dtsch Arztebl Int 106(41):664–668. https://doi.org/10.3238/arztebl.2009.0664
Edelman SV, Polonsky WH (2017) Type 2 diabetes in the real world: the elusive nature of glycemic control. Diabetes Care 40(11):1425–1432. https://doi.org/10.2337/dc16-1974
Nathan DM, Buse JB, Davidson MB et al (2009) Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 32(1):193–203. https://doi.org/10.2337/dc08-9025
Acknowledgements
This study is funded by AstraZeneca. MT is supported by a Monash University Postgraduate Research Scholarship and a Baker IDI Bright Sparks Scholarship, Australia. JES and DJM are supported by National Health and Medical Research Council Senior Research Fellowships, Australia. This work is partially supported by the Victorian OIS program.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
This study was supported by AstraZeneca.
Human and animal rights disclosure
The study was approved by the Monash University Human Research Ethics Committee (number 1441), and the Alfred Ethics Committee (number 64/15) in Australia and in some of the sites, as required by local guidelines.
Informed consent
For this type of study, informed consent is not required.
Additional information
Managed by Massimo Federici.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Tabesh, M., Magliano, D.J., Tanamas, S.K. et al. Diabetes management and treatment approaches outside of North America and West Europe in 2006 and 2015. Acta Diabetol 56, 889–897 (2019). https://doi.org/10.1007/s00592-018-01284-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00592-018-01284-4